News
Regulatory delays could hinder Mind Medicine's patient access and market entry. Read why we are initiating coverage on MNMD ...
Ketamine is only approved by the FDA as an anesthetic, but there is growing interest in using ketamine products to treat ...
Esketamine nasal spray, a rapid-acting anti-depressant, is known to be effective against TRD when administered alongside antidepressants like selective serotonin reuptake inhibitor (SSRI ...
Esketamine combined with a serotonin-norepinephrine reuptake inhibitor (SNRI) for treatment-resistant depression (TRD) was linked to significantly lower rates of several adverse outcomes than ...
FRIDAY, April 4, 2025 (HealthDay News) -- The U.S. Food and Drug Administration (FDA) has delayed the full approval of Novavax’s COVID-19 vaccine. The decision had been expected by April 1 ...
The justices threw out a lower court's decision that the FDA had failed to follow proper legal procedures under a federal law called the Administrative Procedure Act when it rejected the ...
The FDA recalled over 4,000 bags of ground coffee mislabeled as decaffeinated across 15 states. The recall applies to 12-ounce bags of Our Family's Traverse City Cherry Decaf Light Roast.
Dr. Peter Marks sent a letter to Acting FDA Commissioner Sara Brenner on Friday saying that he would resign and retire by April 5 as director of the Center for Biologics Evaluation and Research.
Dr. Peter Marks sent a letter to acting FDA Commissioner Sara Brenner on Friday saying that he would resign and retire by April 5 as director of the Center for Biologics Evaluation and Research.
Greg Nash/The Hill/Bloomberg via Getty; Kevin Dietsch/Getty Dr. Peter Marks, one of the U.S. Food and Drug Administration’s (FDA) top vaccine officials, has resigned. In a resignation letter ...
Dr. Peter Marks, who oversaw the FDA’s vaccine division as director of the Center for Biologics Evaluation and Research, submitted his resignation to acting FDA Commissioner Sara Brenner on Friday.
Dr Peter Marks, the director for the agency’s Center for Biologics Evaluation and Research, submitted his resignation letter to FDA Acting Commissioner Sara Brenner, citing Health and Human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results